Medpace Holdings, Inc. — Q1 2022 Form 10-Q
Reporting period: Three months ended March 31, 2022; comparative period is Q1 2021. Medpace is a global clinical research organization providing Phase I–IV development services to pharmaceutical, biotechnology, and medical-device customers.
Financial performance
| Metric | Q1 2022 | Q1 2021 | Change |
|---|---|---|---|
| Revenue | $330.9 million | $260.0 million | +27.3% |
| Income from operations | $64.2 million | $47.6 million | +34.9% |
| Operating margin | 19.4% | 18.3% | +1.1 percentage points |
| Net income | $61.3 million | $43.3 million | +41.6% |
| Diluted EPS | $1.69 | $1.14 | +48.2% |
| Operating cash flow | $46.3 million | $57.3 million | Down $11.1 million |
Net margin was approximately 18.5%, versus 16.7% in Q1 2021. Revenue growth was driven primarily by Oncology, Metabolic, Central Nervous System, and Cardiology. Direct costs rose 27.9%, including higher reimbursed expenses and personnel costs; SG&A increased 14.1%. The effective tax rate declined to 6.1% from 10.7%, mainly due to increased share-based compensation tax benefits and benefits from uncertain tax positions.
Cash, liquidity, and capital structure
- Cash and cash equivalents were $82.8 million at March 31, 2022, down from $461.3 million at year-end, primarily reflecting share repurchases.
- Operating cash flow was $46.3 million; investing cash outflow was $11.2 million, including $9.3 million of property and equipment spending.
- Financing cash outflow was $412.1 million, principally the $425.9 million spent repurchasing 2.75 million shares. The average repurchase price was $155.09 per share.
- No borrowings were outstanding under the $250 million revolving credit facility; $249.8 million was available, with $0.2 million in letters of credit. The facility expires March 31, 2023.
- No debt was reported. Operating lease liabilities totaled $160.1 million. Current assets were $356.0 million and current liabilities $579.4 million at quarter-end.
- Remaining repurchase authorization was approximately $264.6 million. Shareholders’ equity fell to $605.0 million from $952.9 million, largely reflecting the repurchase and retirement of shares.
Backlog, outlook, and risks
- Net new business awards were $423.0 million, compared with $356.2 million a year earlier. Backlog increased 28.0% year over year to $2.088 billion; the company expected $1.060–$1.080 billion to convert to revenue over the next 12 months.
- Approximately $2.4 billion of performance obligations remained for active projects. Backlog and awards are not assured indicators of future revenue and may change with cancellations, scope changes, timing, and foreign exchange.
- The filing provides no quantitative full-year revenue or earnings guidance. Management described pandemic-related impacts as expected to be temporary, but noted continuing risks to site access, enrollment, and trial start-up. Future financial effects could not be reasonably estimated.
- Risks highlighted include inflation and competitive pricing pressure on margins, international regulatory and operating exposure, foreign-exchange and collection risks, and potential trial delays or suspensions related to the Russia-Ukraine conflict.
- Legal matters were described as ordinary-course and immaterial based on management’s assessment. Purchase commitments for project supplies totaled $11.9 million through 2027.
Notable items and investor verification points
- Review the scale and timing of the $425.9 million buyback against the sharp decline in cash, the remaining authorization, and operating cash generation.
- Verify conversion of backlog and awards into recognized revenue, particularly given customer cancellation rights and study execution risks.
- Monitor receivables and unbilled balances, which increased to $224.8 million, and the $38.2 million operating cash use from their quarter-over-quarter increase.
- Assess related-party transactions and governance: executives, including the CEO, have connections to customers LIB Therapeutics and CinRx; the CEO or family-related entities own properties leased by Medpace and control an aviation provider. Q1 revenue from LIB and CinRx was $7.4 million and $5.8 million, respectively.
- Track facility renewal or refinancing, lease commitments, margin effects of inflation and pricing, and continuing COVID-19 and geopolitical disruptions.